Blinatumomab + Cytarabine + Methotrexate + Ponatinib
Phase 2RecruitingDevelopment Stage
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, t(9;22)
Nov 29, 2017 → Nov 30, 2027
About Blinatumomab + Cytarabine + Methotrexate + Ponatinib
Blinatumomab + Cytarabine + Methotrexate + Ponatinib is a phase 2 stage product being developed by Amgen for Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03263572. Target conditions include Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression.
What happened to similar drugs?
0 of 1 similar drugs in Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03263572 | Phase 2 | Recruiting |
Competing Products
4 competing products in Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 42 |
| BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + [14C] BMS-813160 + Placebo + BMS-813160 + BMS-813160 | Bristol Myers Squibb | Phase 1 | 29 |
| dasatinib + dasatinib | Bristol Myers Squibb | Phase 3 | 40 |
| Ruxolitinib + Enasidenib | Incyte | Phase 2 | 32 |